Protocol EC-FV-05: An Open-label, Multi-center, Extension Study of EC145 Administered Weeks 1 and 3 of a 4-Week Cycle in Subjects Enrolled in a Previous Study With EC145
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Vintafolide (Primary)
- Indications Endometrial cancer; Non-small cell lung cancer; Ovarian cancer
- Focus Adverse reactions
- Sponsors Endocyte; Merck Sharp & Dohme
- 23 Aug 2017 Status changed from active, no longer recruiting to completed.
- 19 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 05 Jun 2014 Planned End Date changed from 1 Dec 2016 to 1 Apr 2018 as reported by ClinicalTrials.gov record.